SCHEMBL5286912

SCHEMBL5286912

[CH2]n1c(=O)oc2cc(C)ccc21

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MIF P14174 3/20 0.53
CD74 P04233 1/20 0.42
KMT2A Q03164 4/20 0.41
MEN1 O00255 2/20 0.41
POLB P06746 1/20 0.41
PKM P14618 1/20 0.41
NOS1 P29475 1/20 0.41
ASAH1 Q13510 1/20 0.40
PTGS2 P35354 3/20 0.40
NPC1 O15118 1/20 0.40
TSHR P16473 1/20 0.40
RAB9A P51151 1/20 0.40
ALDH1A1 P00352 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
THRB P10828 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5287521 0.85 MIF (0.53) MIFCD74KMT2AMEN1POLB
SCHEMBL1025445 0.79 PKM (0.58) MIFKMT2AMEN1POLBPKM
SCHEMBL5539784 0.78 CD74 (0.42) MIFCD74KMT2AMEN1POLB
SCHEMBL4997130 0.78 IDO1 (0.45) KMT2APKMNOS1ASAH1NPC1
SCHEMBL5541833 0.78 NPC1 (0.53) MIFKMT2APKMASAH1NPC1
SCHEMBL16997521 0.76 MIF (0.51) MIFCD74KMT2AMEN1POLB
SCHEMBL13367743 0.75 MIF (0.66) MIFCD74KMT2AMEN1POLB
SCHEMBL13367652 0.75 MIF (0.50) MIFCD74KMT2AMEN1POLB
SCHEMBL10165252 0.74 ASAH1 (0.52) MIFCD74KMT2AMEN1POLB
SCHEMBL2149119 0.73 MIF (0.62) MIFCD74KMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO claimed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US claimed
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 MIF 636/4885CD74 475/4885KMT2A 4422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.